Publications by authors named "Rosie Kryczka"
Article Synopsis
- Ovarian and endometrial cancers with -amplification often resist standard treatments, indicating a significant clinical challenge.
- A study identified that the PKMYT1 inhibitor, lunresertib, combined with the ATR inhibitor, camonsertib, can effectively target -amplification-related replication stress, leading to increased cancer cell death.
- This combination therapy demonstrated durable antitumor effects and improved survival in xenografts from patients and cell lines, suggesting a new treatment strategy focused on enhancing CDK1 activity for these cancer types.
PKMYT1 is a regulator of CDK1 phosphorylation and is a compelling therapeutic target for the treatment of certain types of DNA damage response cancers due to its established synthetic lethal relationship with amplification. To date, no selective inhibitors have been reported for this kinase that would allow for investigation of the pharmacological role of PKMYT1. To address this need compound was identified as a weak PKMYT1 inhibitor.
View Article and Find Full Text PDF